Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Frankfurt - Delayed Quote EUR

Immunic, Inc. (10VA.F)

Compare

1.2360

+0.1610

+(14.98%)

At close: February 21 at 5:32:30 PM GMT+1

Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week

Key Insights Significant control over Immunic by retail investors implies that the general public has more power to...

Simply Wall St. 3 hours ago

IMUX
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), demonstrated a dose-dependent increase of endogenous glucagon-like peptide-1 (GLP-1) levels in a post hoc analysis of patients from its phase 1b clinical trial in celiac disease. IMU-85

PR Newswire 2 days ago

IMUX
Immunic to Participate in Investor and Scientific Conferences in February

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February:

PR Newswire 18 days ago

IMUX
Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today highlighted its 2024 accomplishments and upcoming milestones.

PR Newswire last month

IMUX
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit Virtual Conference presentations are now available for on-demand viewing. Participants and those ...

ACCESS Newswire 2 months ago

IMUX

OESX

SPGC
Immunic, Inc. to Participate in Investor Conference in December

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 5, 2024, at 11:30 am ET, during the Piper Sandler 36th Annual Healthcare Conference, taking place December 3-5, 2024, in New York.

PR Newswire 2 months ago

IMUX
Insider Buys Additional US$100k In Immunic Stock

Investors who take an interest in Immunic, Inc. ( NASDAQ:IMUX ) should definitely note that the Independent Director...

Simply Wall St. 3 months ago

IMUX
Immunic announces publication of IMU-856 data

Immunic (IMUX) announced that the data from its phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, has been published in the peer reviewed journal, The Lancet Gastroenterology & Hepatology. The first two portions of the phase 1 clinical trial, Parts A and B, were single ascending dose and multiple ascending dose, double-blind, placebo-controlled studies in a total of 71 healthy human subjects. Single and multiple ascendi

TipRanks 3 months ago

IMUX
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the data from its phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), has been published in the peer reviewed journal, The Lancet Gastroenterology & Hepatology. Lead authored by Dr. A. James Daveson, Gastroen

PR Newswire 3 months ago

IMUX
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges

Immunic Inc (IMUX) reports promising clinical trial advancements and strategic partnerships, despite increased R&D expenses and market competition.

GuruFocus.com 3 months ago

IMUX
Immunic: Q3 Earnings Snapshot

NEW YORK (AP) — Immunic, Inc. IMUX) on Thursday reported a loss of $24.4 million in its third quarter. On a per-share basis, the New York-based company said it had a loss of 24 cents.

Associated Press Finance 3 months ago

IMUX
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the third quarter and nine months ended September 30, 2024, and provided a corporate update.

PR Newswire 3 months ago

IMUX
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2024, including a corporate update, on Thursday, November 7, 2024, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.

PR Newswire 3 months ago

IMUX
Immunic to Participate in Industry, Scientific and Investor Conferences in November

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry, scientific and investor conferences in November:

PR Newswire 3 months ago

IMUX
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced a positive outcome of the non-binding, interim futility analysis of its phase 3 ENSURE program, investigating lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), for the treatment of relapsing multiple sclerosis (RMS). Based on the outcome of the interim futilit

PR Newswire 3 months ago

IMUX
We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 4 months ago

IMUX
Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ...

Immunic Inc (IMUX) showcases encouraging trial results and strategic leadership changes amid financial hurdles and funding explorations.

GuruFocus.com 4 months ago

IMUX
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of key data at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), highlighting Immunic's lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium's (IMU-838) therapeutic potential in multiple sclerosis (MS).

PR Newswire 5 months ago

IMUX
Owning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX),

Key Insights Given the large stake in the stock by institutions, Immunic's stock price might be vulnerable to their...

Simply Wall St. 5 months ago

IMUX
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced enrollment of the first patient in an investigator-sponsored phase 2 clinical trial of its lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), entitled, "Randomized Adaptive Assessment of Post COVID Syndrome Treatments_Reducing Inflammatory Activity in Patients

PR Newswire 5 months ago

IMUX

Performance Overview

Return	10VA.F	S&P 500
YTD	+22.62%	+2.24%
1-Year	+3.00%	+20.70%
3-Year	-88.35%	+38.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Immunic, Inc. (10VA.F)

Immunic, Inc.'s (NASDAQ:IMUX) largest shareholders are retail investors who were rewarded as market cap surged US$24m last week

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Immunic to Participate in Investor and Scientific Conferences in February

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

Immunic, Inc. to Participate in Investor Conference in December

Insider Buys Additional US$100k In Immunic Stock

Immunic announces publication of IMU-856 data

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges

Immunic: Q3 Earnings Snapshot

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully

Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ...

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Owning 39% shares,hedge funds owners seem interested in Immunic, Inc. (NASDAQ:IMUX),

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Performance Overview